Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic

    August 31, 2021 | Strategy, chronic disease, hepatitis, hepatitis C, infectious disease, patient engagement 

    Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’ approaches to combatting the disease and explore the importance of a de-centralized strategy that overcomes the stigma preventing patients from seeking treatment.

    - PMLiVE

    This year’s World Hepatitis Day theme, ‘Hepatitis Can’t Wait,’ stresses the urgency of testing and treating viral hepatitis, as well as removing the stigma surrounding the disease and providing support for patients.

    Treatment for hepatitis C has evolved dramatically over the past decade. The introduction of direct-acting-antivirals has revolutionized the treatment landscape, leading the World Health Organization to set a global target to eliminate the disease as a public health problem by 2030.

    Today hepatitis C is a curable disease. It takes just 8–12 weeks of oral therapy to successfully cure close to 100% of patients with chronic hepatitis C virus infection. Gone are the days of thrice-weekly injections, low cure rates, and a myriad of side effects. The treatment algorithm is far simpler, the therapies are less invasive, the side effects typically milder and much less frequent, and the time patients spend taking medication is far shorter. There is limited need for pre-treatment assessments, on-treatment monitoring, and post-treatment follow-up, making it much easier for patients to fit treatment into their daily lives.

    Despite huge advances in the field, the burden of hepatitis C remains a significant public health problem. The World Health Organization (WHO) estimates that 71 million people globally have chronic hepatitis C.[1] Yet, 80% are unaware of their infection status, and a significant number of those will develop cirrhosis or liver cancer if not treated.[2] So, if a cure exists, why are so many people still infected with hepatitis C virus and suffering from the consequences of ongoing chronic infection and liver damage?

    Download the full article to learn about: 

    • The approaches different countries are taking to eliminating hepatitis C
    • Successful strategies for engaging hard-to-reach patients
    • Why treating patients in active addiction is crucial for tackling the disease
    • Iceland case study

    DOWNLOAD THE FULL ARTICLE HERE

    This content was provided by Avalere Health

    Company Details

    - PMLiVE

    Avalere Health

    Email
    Website

     Latest Content from  Avalere Health 

    Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

    Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

    Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

    As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

    Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

    As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

    Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies

    Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

    Archetypes: Rethinking go-to-market expectations to drive commercial success

    In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

    Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer

    Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

    Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

    Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

    The challenges of reimbursement and innovative pricing for cell and gene therapies

    Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

    Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

    Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

    Fishawack Health welcomes Mario Muredda as its new President of Marketing

    Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.